Thread by @TransfusionWM

In the general haematology top scoring abstracts session, initial results from the PADDOCK study of APL-2 in treatment naive patients with PNH pnhstudy.com/paddock/

And next the identification of IKRZF5 mutation as the cause of thrombocytopenia. Important to have accurate diagnosis to prevent unnecessary treatment for ??ITP and identify need for follow-up for any associated abnormalities (or none) #BSH2019

REALISM is a UK wide real life study of current rx of myelofibrosis. JAK2 inhibitors now recommended as first line for patients with symptomatic MF
BUT only NICE funded if int-2 or high risk disease #BSH2019
BSH guidelines here onlinelibrary.wiley.com/doi/full/10.11…

Most common symptoms of pts with MF are fatigue and weight loss. 13% had no documented symptoms. 47% of all pts were not started on treatment at diagnosis #BSH2019

Next up the results of a national audit of IVIg use for ITP, a @HaemSTAR_UK -led study haemstar.org #BSH2019

@HaemSTAR_UK is a brilliant initiative of predominantly non research SpRs with a consultant mentor building a network to get widespread co-ordinated data collection at multiple sites.

IVIg in ITP was a ripe topic for national audit following NHSE guidance recommending a single dose of 1g/kg, repeated only if clinically indicated #BSH2019 #blooducation

139 investigators, 39 sites and 10.5 weeks = data on 978 patients! An excellent model #BSH2019

71.2% first treatments were in line with current guidance. CR 35.7% and PR in 29.9%, in keeping with previous data #BSH2019

No difference in platelet response over time whether patient were given 1g/kg once or 1g/kg daily on 2 consecutive days (slightly faster response with double dose but ??clinically relevant) #BSH2019

Lovely talk from @PipNicolson